John Colen, MD
Urology · Houston, TXNPI 1982934063
Payments from drug & device makers
Across 40 payments — averaging $228.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Boston Scientific$2K
- Biotissue Holdings Inc.$490
- Procept Biorobotics Corporation$137
- 180 Medical, Inc.$45
- Convatec Inc.$45
- plus $41 from 2 others
What the payments were for
- Travel & lodging$3,15634%
- Food & beverage$1,49416%
- Education$4,50049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $6,294 |
| Boston Scientific | 10 | $2,098 |
| Biotissue Holdings Inc. | 3 | $490 |
| Procept Biorobotics Corporation | 1 | $137 |
| 180 Medical, Inc. | 2 | $45 |
| Convatec Inc. | 2 | $45 |
| Neotract Inc. | 1 | $26 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$4,500
- Da Vinci Surgical System$1,392
- AquaBeam Robotic System$137
- GENERAL BPH$120
How this compares
$9,150 in reported general payments places this provider in the 70th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 173 | $86,882 |
| Tamsulosin Hcl | 1,024 | $46,904 |
| Oxybutynin Chloride ErOxybutynin Chloride | 342 | $20,526 |
| GemtesaVibegron | 33 | $18,089 |
| Finasteride | 394 | $12,396 |
| Trospium Chloride ErTrospium Chloride | 80 | $12,230 |
| Testosterone Cypionate | 86 | $4,064 |
| Darifenacin ErDarifenacin Hydrobromide | 26 | $3,921 |
| Solifenacin Succinate | 33 | $3,285 |
| Potassium Citrate ErPotassium Citrate | 31 | $3,188 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 50 | $2,468 |
| Dutasteride | 30 | $2,312 |
| Desmopressin Acetate | 49 | $2,210 |
| Sildenafil Citrate | 24 | $2,113 |
| Estradiol | 28 | $1,821 |
Paid to pharmacies, not to this prescriber.
Other urology in Houston
- Zvi SchiffmanHouston$17.8M
- Jose KaramHouston$5.7M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Brian ChapinHouston$1.1M
- Arun RaiHouston$1M
- Ashish KamatHouston$957K
- Donald GriffithHouston$732K
- Robert CornellHouston$695K
- John DavisHouston$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.